Streetbeat News

NOVN

Novan Inc

http://www.novan.com/

CEO

G. Kelly Martin

Employees

Industry

Pharmaceutical Preparation Manufacturing

novan, inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. we believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.

Open

0.14

Mkt cap

2.6M

Volume

6.9M

High

0.14

P/E Ratio

-0.11

52-wk high

3.33

Low

0.08

Div yield

N/A

52-wk low

0.08

The FDA has approved Verrica Pharmaceuticals' Ycanth solution for molluscum contagiosum in patients two years and older. Following this, Needham upgraded Verrica's stock to Buy from Hold with a price target of $10. The analysts believe that the current valuation underappreciates Ycanth's potential to become standard-of-care for molluscum and its potential for wider use in other types of warts. The most near-term potential competitor to Ycanth is a product developed by Novan Inc, which recently filed for bankruptcy.

Portfolio Pulse from Vandana Singh

July 25, 2023 | 5:04 pm

During Tuesday's pre-market session, several healthcare stocks experienced significant movements. Bullfrog AI Hldgs, Enzo Biochem, Aravive, Novan, Biotricity, and Alpha Tau Medical saw increases, while Humanigen, NeuroOne Medical Tech, Bellerophon Therapeutics, Stoke Therapeutics, Bionomics, and ViewRay experienced decreases.

Portfolio Pulse from Benzinga Insights

July 25, 2023 | 1:05 pm

During Friday's intraday session, several healthcare stocks experienced significant movements. Quoin Pharmaceuticals, Fresh Tracks Therapeutics, LifeMD, Biodexa Pharmaceuticals, bluebird bio, and Fortress Biotech saw their stocks rise by 36.1%, 33.54%, 26.34%, 23.71%, 18.8%, and 15.92% respectively. On the other hand, Redhill Biopharma, Mallinckrodt, Aceragen, BioSig Technologies, Avinger, and Novan saw their stocks decline by 23.8%, 16.21%, 15.08%, 14.34%, 14.29%, and 13.52% respectively.

Portfolio Pulse from Benzinga Insights

July 21, 2023 | 5:31 pm

On Friday, 54 companies hit new 52-week lows. The largest company in terms of market cap to set a new 52-week low was NovoCure (NASDAQ:NVCR), while the smallest was Ucommune International (NASDAQ:UK). Sigma Additive Solutions (NASDAQ:SASI) saw the largest move, with shares plummeting 27.56%. Greenbrook TMS (NASDAQ:GBNH) shares were the most resilient, moving up 0.0% in response to hitting its 52-week low.

Portfolio Pulse from Benzinga Insights

July 21, 2023 | 5:24 pm

In Thursday's after-market session, several health care stocks saw significant movement. Evelo Biosciences, TFF Pharmaceuticals, Anitra, Intensity Therapeutics, Aptevo Therapeutics, and Mesoblast saw gains ranging from 6.58% to 11.7%. On the other hand, BioSig Technologies, Trinity Biotech, Novan, Trxade Health, Cingulate, and Intuitive Surgical saw declines ranging from 4.54% to 7.2%. Intuitive Surgical's Q2 earnings report was released.

Portfolio Pulse from Benzinga Insights

July 20, 2023 | 9:32 pm

Several healthcare stocks experienced significant movement in Wednesday's after-market session. Gainers included Dynatronics (DYNT), Novan (NOVN), Trinity Biotech (TRIB), 9 Meters Biopharma (NMTR), Tivic Health Systems (TIVC), and Oncternal Therapeutics (ONCT). Losers included Healthcare Triangle (HCTI), EUDA Health Holdings (EUDA), Enochian BioSciences (ENOB), Biodexa Pharmaceuticals (BDRX), Trevena (TRVN), and Evelo Biosciences (EVLO).

Portfolio Pulse from Benzinga Insights

July 19, 2023 | 9:32 pm

The article lists the stocks that gained and lost the most in Tuesday's mid-day session. Some of the gainers include Pieris Pharmaceuticals, The Singing Machine Company, Biophytis, iCAD, Aridis Pharmaceuticals, and The Charles Schwab Corporation. The losers include 9 Meters Biopharma, Fangdd Network Group, Lixte Biotechnology Holdings, Masimo Corporation, and Aptevo Therapeutics.

Portfolio Pulse from Lisa Levin

July 18, 2023 | 5:00 pm

Biophytis S.A. (BPTS) shares surged 53.9% after signing a partnership with SEQENS to produce Sarconeos (BIO101) active compound. Aridis Pharmaceuticals, Inc. (ARDS) shares gained 41.8% after EMA announced positive feedback on the company's proposed Phase 3 study AR-301. Karyopharm Therapeutics Inc. (KPTI) rose 26.1% after receiving FDA Fast Track Designation for Selinexor for Myelofibrosis. 9 Meters Biopharma, Inc. (NMTR) fell 59% and Masimo Corporation (MASI) fell 27.3% after reporting weak preliminary revenue results for Q2.

Portfolio Pulse from Lisa Levin

July 18, 2023 | 12:12 pm

U.S. stocks traded higher with the Dow Jones gaining 0.25%. Guaranty Bancshares (GNTY) reported better-than-expected Q2 results. ProMIS Neurosciences (PMN), BridgeBio Pharma (BBIO), and GreenPower Motor Company (GP) saw their shares rise after positive news. Novan (NOVN), ViewRay (VRAY), and Jiuzi Holdings (JZXN) shares fell due to various reasons. Oil traded down 1.8% to $74.08.

Portfolio Pulse from Lisa Levin

July 17, 2023 | 7:05 pm

During Monday's intraday session, several healthcare stocks experienced significant movements. BridgeBio Pharma, Acumen Pharmaceuticals, Quantum-Si, Lixte Biotech Hldgs, argenx, and Rockwell Medical saw their shares rise by 78.8%, 62.89%, 33.91%, 28.91%, 27.33%, and 24.29% respectively. On the other hand, ViewRay, Novan, Tivic Health Systems, Virios Therapeutics, Apellis Pharmaceuticals, and Minerva Surgical saw their shares fall by 78.5%, 69.64%, 29.31%, 22.94%, 21.72%, and 17.3% respectively.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.